paragraph (2)(B)(ii). The Secretary may impose a civil monetary penalty in an amount not to exceed $100,000 on a wholesaler or manufacturer that refuses a request for information about charges or prices by the Secretary in connection with a survey under this subparagraph or knowingly provides false information. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subparagraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a). (10) Civil monetary penalty In lieu of applying paragraph (1) for a calendar quarter, in the case of a manufacturer of a rebatable drug who has failed to comply with the requirements under paragraph (2)(B)(i) for such drug for the rebate period with respect to such calendar quarter, the Secretary may, pursuant to regulations, impose a civil monetary penalty on such manufacturer in an amount not to exceed 2 percent of the total expenditures under this part for such drug for such failure with respect to such drug and quarter. The provisions of section 1128A (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subparagraph in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a). (11) Study and report (A) Study The Secretary shall conduct a study of the feasibility of and operational issues involved with the following: (i) Including multisource drugs (as defined in section 1847A(c)(3)(C)) in the rebate system under this subsection. (ii) Including drugs and biologicals paid for under MA plans under part C in the rebate system under this subsection. (iii) Including drugs excluded under paragraph (3) in the rebate system under this subsection. (B) Report Not later than 3 years after the date of the enactment of this subsection, the Secretary shall submit to Congress a report on the study